Arpasiri SRİSRATTAKARN, Chonthicha CHAİYAPOKE, Sirikarn BOONCHAROEN, Sujintana WONGTHONG, Aroonwadee CHANAWONG, Patcharaporn TİPPAYAWAT, Ratree TAVİCHAKORNTRAKOOL, Aroonlug LULİTANOND

Synergistic effect of vancomycin combined with cefotaxime, imipenem, or meropenem against Staphylococcus aureus with reduced susceptibility to vancomycin

Background/aim: We investigated the synergistic effect between vancomycin and β-lactams against vancomycin-susceptible (VSSA) and nonsusceptible MRSA isolates [heterogeneous vancomycin-intermediate S. aureus (hVISA) and VISA]. Materials and methods: A total of 29 MRSA, including 6 VISA, 14 hVISA, and 9 VSSA isolates, were subjected to a microbroth dilution-minimum inhibitory concentration (MIC) checkerboard using vancomycin combined with cefotaxime, imipenem, or meropenem. To confirm synergistic activity, the representative strains of VISA, hVISA, and VSSA were then selected for the time-kill curve method. Results: The combination of vancomycin with imipenem, meropenem, or cefotaxime exhibited synergistic effects against 17 (2 VISA, 9 hVISA, and 6 VSSA), 14 (3 VISA, 9 hVISA and 2 VSSA), and 5 (3 VISA and 2 hVISA) isolates, respectively. Additive and indifferent effects were found in the remaining isolates, but no antagonistic effect was observed. Using time-kill assay, the vancomycin combined with either imipenem or cefotaxime demonstrated synergism against both VISA and hVISA isolates, while the synergistic effect with meropenem was obtained only in the VISA isolates. Conclusion: This study demonstrated in vitro enhanced antibacterial activity of vancomycin plus β-lactams against clinical hVISA or VISA isolates. These combinations may be an alternative treatment for MRSA infections in clinical practice.Key words: β-Lactams, methicillin-resistant Staphylococcus aureus, synergy, vancomycin, vancomycin resistance

PDF

___

1. Chua K, Howden BP. Treating Gram-positive infections: vancomycin update and the whys, wherefores and evidence base for continuous infusion of anti-Gram-positive antibiotics. Current Opinion in Infectious Diseases 2009; 22 (6): 525-534. doi: 10.1097/QCO.0b013e328331fbcd
2. Hiramatsu K, Hanaki H, Ino T, K Yabuta, T Oguri et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. Journal of Antimicrobial Chemotherapy 1997; 40 (1): 135-136. doi: 10.1093/jac/40.1.135
3. Lai CC, Chen CC, Chuang YC, Chuang YC, Tang HJ. Combination of cephalosporins with vancomycin or teicoplanin enhances antibacterial effect of glycopeptides against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and VISA. Scientific Reports 2017; 7: 41758. doi: 10.1038/srep41758
4. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124 (5): 1789-1797
5. Davis JS, Van Hal S, Tong SY. Combination antibiotic treatment of serious methicillin-resistant Staphylococcus aureus infections. Seminar in Respiratory and Critical Care Medicine 2015; 36 (1): 3-16. doi: 10.1055/s-0034-1396906
6. Climo MW, Patron RL, Archer GL. Combinations of vancomycin and β-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin. Antimicrobial Agents and Chemotherapy 1999; 43 (7): 1747- 1753. doi:10.1128/AAC.43.7.1747
7. Barber KE, Werth BJ, Ireland CE, Stone NE, Nonejuie P et al. Potent synergy of ceftobiprole plus daptomycin against multiple strains of Staphylococcus aureus with various resistance phenotypes. Journal of Antimicrobial Chemotherapy 2014; 69 (11): 3006-3010. doi: 10.1093/jac/dku236
8. Sieradzki K, Tomasz A. Suppression of β-lactam antibiotic resistance in a methicillin-resistant Staphylococcus aureus through synergic action of early cell wall inhibitors and some other antibiotics. Journal of Antimicrobial Chemotherapy 1997; 39 Suppl A: 47-51. doi: 10.1093/jac/39.suppl_1.47
9. van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrobial Agents and Chemotherapy 2013; 57 (2): 734-744. doi: 10.1128/ AAC.01568-12
10. Kondo Y, Ito T, Ma XX, Watanabe S, Kreiswirth BN et al. Combination of multiplex PCRs for staphylococcal cassette chromosome mec type assignment: rapid identification system for mec, ccr, and major differences in junkyard regions. Antimicrobial Agents and Chemotherapy 2007; 51 (1): 264- 274. doi: 10.1128/AAC.00165-06
11. Wongthong S, Dutchanutouch K, Namsaengkang V, Chanawong A, Wilailuckana C et al. Performance of vancomycin and teicoplanin disk diffusion test in isogenic vancomycin non-susceptible Staphylococcus aureus. The Journal of Infection in Developing Countries 2015; 9 (2): 157- 164. doi: 10.3855/jidc.5059
12. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. 11th ed. CLSI document M07-A11. Wayne, PA, USA: Clinical and Laboratory Standards Institute; 2014.
13. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. 28th ed. CLSI document M100-S28. Wayne, PA, USA: Clinical and Laboratory Standards Institute; 2018.
14. Jacqueline C, Navas D, Batard E, Miegeville AF, Le Mabecque V et al. In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 2005; 49 (1): 45-51. doi: 10.1128/AAC.49.1.45-51.2005
15. Kobayashi Y. Study of the synergism between carbapenems and vancomycin or teicoplanin against MRSA, focusing on S-4661, a carbapenem newly developed in Japan. Journal of Infection and Chemotherapy 2005; 11 (5): 259-261. doi: 10.1007/s10156- 005-0402-2
16. Sy CL, Huang TS, Chen CS, Chen YS, Tsai HC et al. Synergy of β-lactams with vancomycin against methicillin-resistant Staphylococcus aureus: correlation of disk diffusion and checkerboard methods. Journal of Clinical Microbiology 2016; 54 (3): 565-568. doi: 10.1128/JCM.01779-15
17. Doern CD. When does 2 plus 2 equal 5? A review of antimicrobial synergy testing. Journal of Clinical Microbiology 2014; 52 (12): 4124-4128. doi: 10.1128/JCM.01121-14
18. Silva LV, Araújo MT, Santos KR, Nunes AP. Evaluation of the synergistic potential of vancomycin combined with other antimicrobial agents against methicillin-resistant Staphylococcus aureus and coagulase-negative Staphylococcus spp. strains. Memorias do Instituto Oswaldo Cruz 2011; 106 (1): 44-50. doi: 10.1590/s0074-02762011000100007
19. Sieradzki K, Tomasz A. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. Journal of Bacteriology 1997; 179 (8): 2557-2566. doi: 10.1128/jb.179.8.2557-2566.1997
20. Watanakunakorn C. Mode of action and in-vitro activity of vancomycin. Journal of Antimicrobial Chemotherapy 1984; 14 Suppl D: 7-18. doi: 10.1093/jac/14.suppl_d.7.
21. Baquero F, Culebras E, Patrón C, Pérez-Díaz JC, Medrano JC et al. Postantibiotic effect of imipenem on Gram-positive and Gram-negative microorganisms. Journal of Antimicrobial Chemotherapy 1986; 18 Suppl E: 47-59. doi: 10.1093/jac/18. supplement_e.47
22. Odenholt-Tornqvist I, Lowdin E, Cars O. Comparative in vitro pharmacodynamics of BO-2727, meropenem and imipenem against gram-positive and gram-negative bacteria. Clinical Microbiology and Infection 1997; 3 (1): 73-81. doi: 10.1111/ j.1469-0691
23. Benquan W, Yingchun T, Kouxing Z, Tiantuo Z, Jiaxing Z et al. Staphylococcus heterogeneously resistant to vancomycin in China and antimicrobial activities of imipenem and vancomycin against it. Journal of Clinical Microbiology 2002; 40 (3): 1109-1112. doi: 10.1128/JCM.40.3.1109-1112.2002
24. Mohammadi-Berenjestanaki H, Khori V, Shirzad-Aski H, Ghaemi EA. In vitro synergistic effect of vancomycin and some antibacterial agents against clinical methicillin-resistant and sensitive Staphylococcus aureus isolates. Microbial Drug Resistance 2020; 26 (3): 218-226. doi: 10.1089/mdr.2019.0003
25. Fernandez J, Abbanat D, Shang W, He W, Amsler K et al. Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptides-intermediate Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 2012; 56 (3): 1476- 1484. doi: 10.1128/AAC.06057-11
26. Ribes S, Pachón-Ibáñez ME, Domínguez MA, Fernández R, Tubau F et al. In vitro and in vivo activities of linezolid alone and combined with vancomycin and imipenem against Staphylococcus aureus with reduced susceptibility to glycopeptides. European Journal of Clinical Microbiology & Infectious Diseases 2010; 29 (11): 1361-1367. doi: 10.1007/ s10096-010-1007-y
27. Dilworth TJ, Ibrahim O, Hall P, Sliwinski J, Walraven C et al. β-Lactams enhance vancomycin activity against methicillinresistant Staphylococcus aureus bacteremia compared to vancomycin alone. Antimicrobial Agents and Chemotherapy 2014; 58 (1): 102-109. doi: 10.1128/AAC.01204-13
28. Dilworth TJ, Sliwinski J, Ryan K, Dodd M, Mercier RC. Evaluation of vancomycin in combination with piperacillintazobactam or oxacillin against clinical methicillinresistant Staphylococcus aureus isolates and vancomycinintermediate S. aureus isolates in vitro. Antimicrobial Agents and Chemotherapy 2014; 58 (2): 1028-1033. doi: 10.1128/ AAC.01888-13
29. Gritsenko D, Fedorenko M, Ruhe JJ, Altshuler J. Combination therapy with vancomycin and ceftaroline for refractory methicillin-resistant Staphylococcus aureus bacteremia: A case series. Clinical Therapeutics 2017; 39 (1): 212-218. doi: 10.1016/j.clinthera.2016.12.005